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Abstract
Background: Kleefstra syndrome is a rare genetic disorder, with core phenotypic features encompassing developmental
delay/intellectual disability, characteristic facial features – brachy(micro)cephaly, unusual shaped eyebrows, flat face with
hypertelorism, short nose with anteverted nostrils, thickened lower lip, carpmouth with macroglossia - and childhood
hypotonia. Some additional symptoms are observed in different percentage of the patients. Epilepsy is common
symptom as well. The underlying cause of the syndrome is a submicroscopic deletion in the chromosomal region 9q34.3
or disruption of the euchromatin histone methyl transferase 1.
Case presentation: We describe two Hungarian Kleefstra syndrome patients, one with the classic phenotype of the
syndrome, the diagnosis was confirmed by subtelomeric FISH. Meanwhile in our second patient beside the classic
phenotype a new symptom – abnormal antiepileptic drug metabolic response – could be observed. Subtelomere FISH
confirmed the 9q34.3 terminal deletion. Because of the abnormal drug metabolism in our second patient, we performed
array CGH analysis as well searching for other rearrangements. Array CGH analysis indicated a large – 1.211 Mb -, deletion
only in the 9q subtelomeric region with breakpoints ch9:139,641,471-140,852,911.
Conclusions: This is the first report on Kleefstra syndrome in patients describing a classical and a complex phenotype
involving altered drug metabolism.
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Background
Kleefstra syndrome (OMIM 610253) (KS), also known
9q subtelomeric deletion syndrome is a rare genetic dis-
order. The definite incidence is yet unknown, however,
since the widespread application of subtelomeric FISH
and later of array comparative genomic hybridization
(aCGH) a number of new cases were diagnosed.
In the phenotype of the syndrome developmental delay/
intellectual disability, characteristic facial features –
brachy(micro)cephaly, unusual shaped eyebrows, flat
face with hypertelorism, short nose with anteverted
nostrils, thickened lower lip, carp mouth with macro-
glossia - and childhood hypotonia are present in all
of the patients [1]. Additional symptoms, as heart defects,
microcephaly, genital/renal anomaly, recurrent infections,
hearing impairment, tracheo/bronchomalacia are ob-
served in different percentage of the patients. Epilepsy and
psychiatric problems are important and common symp-
toms. While epilepsy is generally well controlled with
standard medications, psychiatric abnormalities include
apathy, aggressive periods, psychosis, autistic features, bi-
polar mood disorders and regression in daily function and
cognitive abilities. There are also some other, less com-
mon symptoms observed, like micropenis, cryptorchidism
and vesicouretheral reflux [1–4]. The underlying cause of
the syndrome is, in the majority of the patients, a sub-
microscopic deletion in the chromosomal region 9q34.3
or disruption of the Euchromatin Histone Methyl Trans-
ferase 1 (Eu-HMTase1), which leads to haploinsufficiency
of the EHMT1 gene. In a study Kleefstra et al. found that
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the minimum critical region is 1.2 Mb and includes 14
genes on the long arm of chromosome 9, which could be
responsible for the 9q subtelomeric deletion syndrome
[5]. No genotype-phenotype correlation was observed
so far with the size of the deletion or between patients
with deletions and those with mutations. Meanwhile in
her study Yatsenko et al. found that specific clinical
endophenotypes are correlated with the extent of the
deletion [6].
There are also some patients showing the core
phenotypic features, but with phenotypic heterogen-
eity of KS in whom Kleefstra et al. identified de novo
mutations in four epigenetic regulator genes, namely
in MBD5, MLL3, SMARCB1 and NR1I3 [7].
We describe KS in Hungarian patients for the first
time. Of the two patients identified one showed the
classic phenotype of the syndrome, a second patient
presented with a new symptom beside the classic




The two hereafter outlined patients were referred to our
clinic because of developmental delay and minor
anomalies.
Patient 1. is a 22 months old girl from the first
pregnancy of a non-consanguineous healthy young
Caucasian couple (father 30 and mother 26 years old).
The only remarkable point in her family history is thy-
roid hypofunction in her mother, in the two sisters of
her mother and in the maternal grandmother. Follow-
ing the diagnosis of a hypoplastic aortic arch at the 26th
week of pregnancy the girl was delivered at 40 weeks of
gestation with a birth weight of 2740 g (10–25 percen-
tiles). An aortic stenosis and coarctation of the aortae
was confirmed by cardiological examination on the first
day of life. Her developmental milestones were delayed.
She turned at 8 months, at 20 months she sat alone
and tried to crawl, and her eye contact evolved around
8 months. Babbling started timely but stopped at
20 months. The objective audiometry showed bilateral
hearing impairment. After adjustment of a hearing aid,
considerable advance was not detected in her auditive
attention. The first epileptic seizure developed at
22 months, which had an adequate therapeutic
response to valproate treatment. Brain MRI detected
symmetrical dilated liquor space with a consequent
gracile hippocampus and subcortical ischemic lesions.
The characteristic features are illustrated in Fig. 1.
She was referred to our institution because of dys-
morphic features at the age of 8 months. At that exam-
ination her weight was 7850 g (50 percentile) height
68 cm (25–50 percentile) and OFC 42 cm (−1 SD), she
had brachycephaly, flat face, midface hypoplasia, down-
slanting palpebral fissure, convergent strabismus, short
nose, high palate, tented lip and severe generalized
hypotonia.
Patient 2. is a 30 month old boy, second child (G2P1)
of a non-consanguineous healthy young couple (father is
34 and mother is 31 years old), his family history was
unremarkable. Because of endometriosis hormone ther-
apy was applied in the mother before pregnancy. In the
fetus dysmaturity was observed from the 34th week of
gestation. He was delivered at 38 weeks of gestation with
a birth weight of 2600 g. His developmental milestones
were delayed, he sat alone at 12 months, stood at
15 months but at 18 months he could not walk. Speech
development was delayed as well, only bubbling was
present at 18 months. The objective audiometry showed
bilateral hearing impairment and in the first year of life
he went through multiple pneumonias. The pulmono-
logical examination revealed tracheomalacia in the
background. His first epileptic seizure developed at
20 months of age, since then the seizures are therapy-
resistant focal seizures. An abnormal AED metabolism
was observed in the boy, namely minimal AED doses
already cause a toxic drug blood level (at 0.03 mg/kg
clonazepam 600 nmol/l blood level and at 11 mg/kg leve-
tiracetam 330 nmol/l blood level occur). At 18 months of
age as he was first examined in our institution his weight
was 10 kg (<5 pc) height was 81 cm (<5 pc) and OFC was
45 cm (<−2 SD). Brachymicrocephaly, flat face, midface
hypoplasia, hypertelorism, short nose, tented lip, thick
lower lip, pointed chin, malformed ears and mild
Fig. 1 Characteristic features of Patient 1
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hypotonia were present. The characteristic features can be
seen in Fig. 2.
Results
Patient 1: GTG-banded chromosomes at the 450 (550)-
band level showed 46, XX normal female karyotype and
subtelomeric FISH confirmed the 9q34.3 terminal dele-
tion. The size of the deletion (2.188 Mb) was established
by array CGH: ch9:138,831,145–141,018,984.
Patient 2: GTG-banded chromosomes at the 450
(550)-band level were normal and subtelomeric FISH
confirmed the 9q34.3 terminal deletion. Performed aCGH
indicate a 1.211 Mb deletion in the 9q subtelomeric region
with the breakpoints ch9:139,641,471–140,852,911.
Conclusions
In the present work we describe two unrelated Hungarian
children with a phenotype characteristic of Kleefstra
syndrome. We made a comparison between the symptoms
of our patients and of patients with 9q subtelomeric
deletions presented by Kleefstra (Table 1) [8].
Initially, regarding Patient 1 with terminal deletion of
9q, she was merely diagnosed using conventional FISH
method. Her facial features (brachycephaly, flat face,
midface hypoplasia, down-slanting palpebral fissure,
short nose, high palate, tented lip) and her mental devel-
opment agree with KS. From her other features the car-
diac anomaly is presented in 50 % of Kleefstra’s cohort,
while in another review with nine patients a cardiac
anomaly was observed in 87 % of the patients [3]. An-
other important symptom of our Patient 1 is the hearing
loss, which was presented in 20 % of Kleefstra’s patients
and is not reported in any patient of Iwakoshi’s cohort.
From 22 months of age she had epileptic seizures well-
controlled with AED. This symptom was presented in
similar rate in Kleefstra’s (30 %) and in Iwakoshi’s (50 %)
group, conversely hypotonia was presented in all of
Iwakoshi’s and in 50 % of Kleefstra’s patients.
Similar to Patient 1 the phenotype and mental devel-
opment of our Patient 2 are also characteristic for KS
Fig. 2 Patient 2 with representative phenotype
Table 1 Clinical features of the presented cases compared with
patients with 9q subtelomeric deletion presented by Kleefstra et al.
Features Kleefstra et al. [8] Patient 1 Patient 2
Gender … - +
MR 28/28 (100) + +
Obesity 5 (16) - -
Microcephaly 25 (83) - +
Brachycephaly 12 (33) - -
Flat face 5 (16) + +
Midface hypoplasia 16 (53) + +
Coarse facies 8 (27) - -
Hypertelorism 15 (50) - +
Synophrys 16 (53) - -
Down slant palpebral fissures 6 (20) + -
Up slant palpebral fissures 5 (16) - +
Arched eyebrows 8 (27) - -
Short nose 17 (57) + +
Anteverted nostrils 12 (33) - -
Carp mouth 23 (77) + +
Macroglossia 12 (33) - -
Natal teeth 1 (3) - -
Thick lower lip 5 (16) - +
Pointed chin 5 (16) - +
Malformed ears 12 (33) - +
Brachydactyly 5 (16) - -
Simian crease 10 (30) - -
Abnormal male genitals 10 (33) -
Cardiac anomaly 15 (50) + -
Anal atresia 2 (7) - -
Alopecia 3 (10) - -
Depigmentation 1 (3) - -
Renal cysts 2 (7) - -
Hydronephrosis 2 (7) - -
Behavioral problems 4 (9) - +
Sleep disturbances 3 (10) - -
Hearing loss 6 (20) + +
Hypotonia 15 (50) + +
Seizures 10 (30) + +
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and the diagnosis was confirmed by FISH examination.
The symptoms of Patient 2 are also evaluated (Table 1).
Behavioral problems which are slightly more common in
patients with intragenic mutations as in patients with
9q34.3 deletion could be observed in Patient 2 at the age
of 3 years [9]. He had a known, but rare symptom of KS,
namely the tracheomalacia, making him susceptible to
pneumonia in his first years of life. At 20 month of age,
first, focal epileptic seizures presented, which became,
after a short therapy responsive period, therapy resistant.
Meanwhile an abnormal AED metabolism became evi-
dent. This feature has not been published as part of KS
and there is no data to be found in the literature that
the haploinsufficiency of EHMT1 causes a symptom as
seen in our patient [10].
As the result of the completed aCGH a 1.211 Mb dele-
tion with the breakpoints ch9:139,641,471–140,852,911
was detected (the deleted region is represented by
probes A_14_P200264→A_16_P38909067). In their
study Yatsenko et al. defined a minimal critical region
of ~700 kb which was deleted in all of the patients
they studied [6]. They suggest that the genes located
in this region are responsible for the common clinical
features and occurrence of other features depends on
the size of the deletions. In another study of these
authors deletions of 28 patients are interpreted, ex-
cept of one all patients’ phenotypes fit with the syn-
drome [11]. In the phenotype of our patient the most
of the symptoms agree with KS, except the abnormal
AED metabolism. On a figure the genes located in
the deletion of our Patient 2 are demonstrated (Fig. 3).
In this region there are some genes which may have
a potential effect on AED metabolism or impact. The
proteins of these genes are expressed in brain and
may influence and limit the penetration, efficacy,
transport and bioavailability of the administered drugs
via altered channel function or neural impairment.
The mechanism of action of levetiracetam is un-
known, but it is thought, that it stimulates synaptic
vesicle protein 2A (SV2A) and inhibiting neurotrans-
mitter release [12]. As regards to clonazepam, this benzo-
diazepine AED also displays inhibitory properties through
the gamma-aminobutyric acid (GABA) receptor, a
ligand-gated chloride ion channel, activated by GABA
[13]. One of the mentioned genes, the ABCA2 gene
encodes a membrane-associated protein by this gene
is an ABC-transporter family member that is highly
expressed in brain tissue and we supposed that it
may have a role in neural development [14]. The
ABCA2 is important in the central nervous system
Fig. 3 Demonstration of genes located in the 1.211 Mb deleted region in 9q34.3 (ch9:139,641,471–140,852,911) of Patient 2
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and in lipid transport necessary for the myelination
process [15–17]. Previous findings of other researchers
suggest that ABCA2 is a novel lysosome-associated mem-
brane protein involved in myelinization or other kinds of
metabolism in the central nervous system [15]. Two
other genes in this region are channel genes. The
PHPT1 gene encodes an enzyme that catalyzes the
dephosphorylation of histidine residues in protein,
and in this way may be part of the group of the
calcium-activated potassium channel genes [18]. Many
human hereditary diseases are associated with abnor-
mal phosphorylation of cellular proteins [19]. The
other one is the CLIC3 gene, which encodes a p64
family member protein that stimulates chloride ion
channel activity [20]. Chloride channels regulate funda-
mental cellular processes including stabilization of cell
membrane potential, transepithelial transport, mainten-
ance of intracellular pH, and regulation of cell volume
and various chloride channels have also been impli-
cated in human diseases [21–23]. Also an interesting
point is the C9orf86 (chromosome 9 open reading frame
86, also known as RABL6) gene, the encoded protein
plays a role in neurotransmitter release in the
membrane of synaptic vesicles and the NPDC1 gene
with a role in neural proliferation, differentiation and
control [24, 25].
Because of ambiguous assumptions, we carried out the
aCGH analysis in case of Patient 1 as well, to find the
probable responsible gene in the background of the
abnormal AED response. Interestingly, after aCGH
examination, the observed deletion in the subtelomeric
region of chromosome 9q was larger in Patient 1 com-
pared to the deletion was found in Patient 2 (2.188 Mb
vs. 1.211 Mb, respectively). Twenty-four additional genes
(UBAC1, LHX3, QSOX2, CARD9, PMPCA, INPP5E,
SEC16A, NOTCH1, MIR126, AGPAT2, LCN10, NACC2,
C9orf69, LOC26102, GPSM1, DNLZ, SNAPC4, SDCCAG3,
C9orf163, EGFL7, FAM69B, SNHG7, SNORA4 and
SNORA17) were detected in Patient 1 beyond the
deleted genes in Patient 2, which also contained the
EHMT1 gene responsible for KS. Subsequently, the
above mentioned genes presumably have no role in
the insufficient drug metabolism and effect, and our
earlier conjecture was disproved. Further clinical and
laboratory investigations are needed to identify the
causes behind the modified AED response, which
presumably could not be explained with chromosomal
abnormalities, rather with DNA sequence alterations
or modified epigenetic mechanisms.
In conclusion, we report two Hungarian KS
patients, one with the classic phenotype of the syn-
drome, while in our other patient beside the classic
phenotype a new symptom – namely an abnormal
drug metabolic response – could be observed.
Materials and methods
Because of the abnormal drug metabolism, we per-
formed aCGH analysis as well in Patient 2 searching
for other rearrangements. Chromosomal microarray
indicated only a large – 1.211 Mb -, deletion in the 9q sub-
telomeric region with the breakpoints ch9:139,641,471–
140,852,911. No other CNV was detected in the index
patient. Parental samples were analyzed using the same
array and gave normal esults. The detailed data of the
detected deletion is depicted on Fig. 3.
Subtelomeric FISH was performed on metaphase
chromosomes prepared from peripheral blood accord-
ing to the protocol of the manufacturer of the probe
used (Vysis ToTelVysion Multicolor FISH Probe Kit,
Abbott Molecular Inc., USA). The specimens were
evaluated in epifluorescent microscope (Zeiss, Axioskop 2).
Visualization and analysis was done using CytoVysion
software (Applied Imaging, UK).
Array CGH was performed using the Agilent Human
Genome G3 Sureprint 8x60K Microarray (Agilent Tech-
nologies, USA), a high resolution 60-mer oligonucleotide
based microarray containing 55,077 60-mer probes,
spanning coding and non-coding genomic sequences
with median spacing of 33 kb and 41 kb, respectively.
Pooled genomic DNA from peripheral blood leuko-
cytes of phenotypically normal males or females from
Promega was used as a reference (Promega Male/Female
Reference DNA, Cat. No.: G1471 and G1521, Promega
Corporation USA).
Labeling and hybridization were carried out based on
the Agilent protocol (Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis – Enzymatic
Labeling Protocol v7.2; July 2012). Washing was per-
formed according to the Agilent Protocol v7.2. Array
image was acquired using an Agilent laser scanner
G2565CA (Agilent Technologies, California, USA) and
analyzed with the Agilent Feature Extraction software
(v10.10.1.1.). Results were presented by Agilent Cytoge-
nomics software (v2.9.2.4). DNA sequence information
refers to the public UCSC database (Human Genome
Browser, Feb 2009 Assembly; GRCh37:hg19).
The deletion detected was aligned to known aberra-
tions listed in publicly available databases, such as the
DECIPHER (Database of Chromosomal Imbalance and
Phenotype in Humans using Ensembl Resources), DGV
(Database of Genomic Variants), Ensembl and ECAR-
UCA (European Cytogeneticists Association Register of
Unbalanced Chromosome Aberrations).
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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